Cell Death and Disease (May 2023)

The HOXD9-mediated PAXIP1-AS1 regulates gastric cancer progression through PABPC1/PAK1 modulation

  • Jiaying Li,
  • Miaomiao Pei,
  • Wushuang Xiao,
  • Xuehua Liu,
  • Linjie Hong,
  • Zhen Yu,
  • Ying Peng,
  • Jieming Zhang,
  • Ping Yang,
  • Jianjiao Lin,
  • Xiaosheng Wu,
  • Zhizhao Lin,
  • Weimei Tang,
  • Fachao Zhi,
  • Guoxin Li,
  • Li Xiang,
  • Aimin Li,
  • Side Liu,
  • Ye Chen,
  • Jide Wang

DOI
https://doi.org/10.1038/s41419-023-05862-5
Journal volume & issue
Vol. 14, no. 5
pp. 1 – 14

Abstract

Read online

Abstract Long non-coding RNAs (lncRNAs) have been functionally characterised in various diseases. LncRNA PAX-interacting protein 1-antisense RNA 1 (PAXIP1-AS1) has reportedly been associated with cancer development. However, its role in gastric cancer (GC) remains poorly understood. Here, we showed that PAXIP1-AS1 was transcriptionally repressed by homeobox D9 (HOXD9) and was significantly downregulated in GC tissues and cells. Decreased expression of PAXIP1-AS1 was positively correlated with tumour progression, while PAXIP1-AS1 overexpression inhibited cell growth and metastasis both in vitro and in vivo. PAXIP1-AS1 overexpression significantly attenuated HOXD9-enhanced epithelial-to-mesenchymal transition (EMT), invasion and metastasis in GC cells. Poly(A)-binding protein cytoplasmic 1 (PABPC1), an RNA-binding protein, was found to enhance the stability of PAK1 mRNA, leading to EMT progress and GC metastasis. PAXIP1-AS1 was found to directly bind to and destabilise PABPC1, thereby regulating EMT and metastasis of GC cells. In summary, PAXIP1-AS1 suppressed metastasis, and the HOXD9/PAXIP1-AS1/PABPC1/PAK1 signalling axis may be involved in the progression of GC.